查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1496017

全球疼痛管理設備市場 - 2024 年至 2029 年預測

Global Pain Management Devices Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 116 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

疼痛管理設備市場預計將從2022年的58.43億美元增加至2029年的132.17億美元，年複合成長率為12.38%。

慢性病的增加和老年人口的增加是影響疼痛管理設備市場的主要因素。疼痛管理採用藥物和設備的精確組合。疼痛管理裝置包括經皮電神經觸發器、神經觸發器、無痛混合虹吸管和射頻消融器。這些設備大多會阻塞疼痛的入口點，阻止疼痛訊號到達大腦。

射頻消融器產生熱量來殺死神經並阻斷疼痛訊號。同樣，神經觸發裝置利用中頻電流來破壞疼痛訊號的侵入。這些設備可以幫助治療獨特的疼痛狀況，例如惡性生長、肌肉骨骼損傷和神經病變疼痛。疼痛管理裝置有助於減少長期鎮靜劑、非類固醇鎮靜劑和其他止痛藥物的威脅。

美國疾病管制與預防中心估計，美國有 5,000 萬人每天承受著持續的慢性疼痛，其中包括 1,960 萬名成年人，他們患有嚴重的疼痛，影響了他們的日常生活或職業。性疼痛。這增加了一些國家的醫療負擔。

隨著技術、穿戴式裝置和小工具越來越融入客戶的日常生活，消費者對這些產品的興趣從新穎性轉向更廣泛使用的疼痛管理技術，疼痛管理設備市場變得越來越有吸引力。

市場促進因素：

  • 老年人口的增加預計將推動市場成長。

由於更好的醫療設施和更少的戰爭，全世界的預期壽命正在增加。隨著人們壽命的延長，疼痛發生的頻率也會增加，因此越來越需要預防和緩解這種不適。

65歲及以上老年人數量的增加預計將有助於疼痛管理設備市場的擴大。根據世界銀行預測，2021年，9.54%的人口將超過65歲。此外，根據聯合國（UN）統計《2019年世界人口展望》，未來30年，世界人口預計將從2019年的77億增加到2050年的97億，世界人口老化將會加劇。 。因此，隨著老年人口的增加，他們將患有慢性背痛和關節炎，導致市場的上升。例如，2023年12月，SPR Therapeutics完成了SPRINT® PNS系統治療慢性下背痛（LBP）的RESET臨床試驗註冊。本研究將比較經皮週邊神經刺激 (PNS) 與慢性下背痛的標準介入治療。

外科手術數量的增加正在推動市場的成長。

疼痛管理設備市場完全是由外科手術的興起所推動的。癌症和神經系統問題等長期疾病的發生率不斷上升，增加了對手術的需求，從而增加了對緩解疼痛創新的需求。由於技術的進步和微創方法的出現，對疼痛管理設備的需求也在擴大。

此外，疾病早期發現和早期治療的新興市場的開拓、公民醫療保健管理意識的提高、獲得醫療保健服務的機會的增加以及政府加強醫療保健計劃的增加也將推動該市場的發展。

市場限制：

  • 使用止痛藥作為疼痛管理主要方法相關的副作用

止痛藥通常是治療的首選藥物，因為它們可能有中毒、嗜睡、便秘和噁心等副作用。成癮藥物會使情況更加複雜。其他疼痛管理方法，例如疼痛管理設備，可以在不使用藥物的情況下減輕疼痛。這些設備可以與物理治療結合或作為獨立治療，以減少副作用並改善疼痛管理。

預計北美將佔據市場佔有率。

由於醫療保健行業的擴張、醫療保健領域的大量投資、創新技術、慢性疼痛發病率上升、環境法規以及全球健康原因（包括易於獲得護理管理），北美在疼痛管理設備市場中佔據著重要地位。美國也以其先進的醫療基礎設施和注重技術進步而聞名。

例如，2023年9月，美國醫療設備製造商波士頓科學公司（Boston Scientific）開發並商業化了治療異位疼痛（一種慢性下背痛）的Intracept®骨內神經消融系統，並宣布達成收購Relievant Medsystems, Inc.的協議。該交易包括 8.5 億美元的預付款以及根據未來三年銷售業績支付的額外成功費用。 Intercept System 是唯一獲得美國食品藥物管理局(FDA) 批准的異位疼痛治療系統，該系統使用定向射頻能源以微創、無植入的門診手術實現功能改善並提供長期疼痛緩解。

由於衰老和生活方式差異而導致的持續性疼痛的普遍存在可能會推動北美對疼痛治療設備的需求增加。北美（尤其是美國）的管理方案支持醫療設備的進步、核准和商業化，以控制疼痛並促進創新和擴張。醫療保健服務的便利性有助於提高疼痛管理設備的採用率。

主要進展

  • 2024 年 4 月 -Medtronic)的 Inceptiv(TM) 獲得 FDA核准，這是一種用於治療慢性疼痛的封閉回路型脊髓刺激設備。Medtronic首款具有閉合迴路功能的 SCS，該設備根據脊髓生物訊號自動即時調整刺激，確保治療與日常生活活動同步。
  • 2023 年 12 月 - Nextim 收到一家經銷商公司的兩套 NBS 6 系統訂單。該系統現在更易於使用，並已在美國和歐盟被核准用於治療重度憂鬱症(MDD)，在歐盟被批准用於治療慢性神經病變疼痛。
  • 2023 年 8 月 - Zynex, Inc. 推出三種新的疼痛管理治療產品。第一個是 Zynex Pro 胸腰骶矯正器具，局部是一種用於脊椎的多功能背部矯正器具；第二個是 Zynex Pro 腕部矯正器具，用於治療手腕相關的疼痛，包括腕隧道症候群；在家或醫院使用。
  • 2023 年 1 月 - 領先的 RPM 和虛擬健康公司 CoachCare 收購了金額位於溫斯頓塞勒姆的 NVOLVE，並擴大了其在南卡羅來納州、北卡羅來納州、喬治亞、德克薩斯州和田納西州的投資組合，增加了NVOLVE 的疼痛、脊椎和維吉尼亞整形外科知識。 FCA Venture Partners 是一家創投公司，投資於早期醫療保健技術和技術支援的服務公司，而 CoachCare 是一家總部位於紐約的遠端患者監護和虛擬健康公司，提供完整的 RPM 支援服務。
  • 2022 年 8 月 - Abbott 的 Proclaim(TM) Plus 脊髓刺激系統獲得 FDA核准，該系統可針對多個疼痛部位提供量身定做的緩解方案，並增加引發疼痛的治療選擇。 FlexBurst360 療法是 Abbott 專有的 BurstDR™ 刺激的下一代，可根據患者治療需求的變化進行調整。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球疼痛管理設備市場：依設備分類

  • 介紹
  • 電刺激設備
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 神經刺激設備
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 止痛輸液泵
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 消融裝置
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第6章全球疼痛管理設備市場：依應用分類

  • 介紹
  • 臉部和偏頭痛
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 神經病變疼痛
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 癌症痛
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 肌肉骨骼疼痛
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第7章全球疼痛管理設備市場：按地區

  • 介紹
  • 北美洲
    • 按設備
    • 按用途
    • 按國家/地區
  • 南美洲
    • 按設備
    • 按用途
    • 按國家/地區
  • 歐洲
    • 按設備
    • 按用途
    • 按國家/地區
  • 中東/非洲
    • 按設備
    • 按用途
    • 按國家/地區
  • 亞太地區
    • 按設備
    • 按用途
    • 按國家/地區

第8章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第9章 公司簡介

  • NeuroMetrix, Inc.
  • Medtronic
  • Boston Scientific Corporation
  • Zynex Medical
  • BioElectronics Corporation
  • Pain Management Technologies
  • SPR Therapeutics
  • Becton, Dickinson, and Company
  • Abbott
  • Nevro Corp
簡介目錄
Product Code: KSI061611753

The global pain management devices market is projected to witness a compounded annual growth rate of 12.38% to reach US$13.217 billion by 2029, up from US$5.843 billion in 2022.

Rising chronic diseases and the geriatric population are the key factors influencing the global pain management devices market. To manage pain, a precise combination of medicines or equipment is used. Pain management devices include transcutaneous electrical nerve triggers, neuro-triggers, the absence of pain mixture siphons, and radiofrequency ablators. A large portion of these devices blocks the pain entryway component to impede the section of pain signs to the mind.

Radiofrequency ablators obliterate nerves by creating warmth to impede the pain signals. Similarly, neuro-trigger devices utilize gentle frequencies of current to obstruct the entry of pain signals. These devices offer assistance in treating distinctive painful conditions like the growth of malignant, musculoskeletal damage, and neuropathic torment. Pain management instruments offer assistance to diminish the threat of long-haul sedatives, non-steroidal calming drugs, and other pain-mitigating medicines.

The Centers for Disease Control and Prevention evaluated that 50 million people within the US endure persistent and chronic daily pain, with adults accounting for 19.6 million that have high-impact chronic and unremitting pain that meddling with their capacity to live their day-to-day lives or their occupations. This is adding to the health care burden of several countries.

The market for pain management devices is appealing as technology, wearables, and gadgets become more integrated into customers' daily lives, and consumer interest in these products shifts from novelty to more widely used pain management techniques.

Market Driver:

  • The growing geriatric population is anticipated to surge the market growth.

People are living longer than ever before worldwide owing to better healthcare facilities and fewer wars. Longer lifespans correspond to a higher occurrence of pain; thus, there is an increasing need to prevent and reduce this discomfort.

The rising number of individuals that over 65 is anticipated to contribute to the pain management devices market expansion. According to the World Bank, in 2021, 9.54% of the population was above 65 years of age. Further, as per the United Nations (UN) statistics for World Population Prospects 2019, the world population is anticipated to rise in the next 30 years, from 7.7 billion in the year 2019 to 9.7 billion in 2050, and the global elderly population is also rising. Thus, with rising elderly population suffers from chronic back pain and arthritis which will lead to a rise in the market. For instance, in December 2023, SPR Therapeutics completed enrollment in the RESET Clinical Trial of the SPRINT(R) PNS System for chronic low back pain (LBP), the largest prospective, multicenter randomized controlled trial to date. The trial compares percutaneous peripheral nerve stimulation (PNS) with standard interventional treatments for chronic LBP.

Increasing the number of surgical procedures carried out will bolster the market growth.

The market for pain management devices is being driven altogether by the rise in surgical operations. The rising rate of long-term sicknesses such as cancer and neurological issues has raised the requirement for surgical methods, which has, in turn, raised the requirement for pain alleviation innovation. The requirement for pain management instruments has also been extended by progresses in innovation and the appearance of negligibly intrusive methods.

Also, it is expected that the market will rise due to the developing accentuation on early illness discovery and treatment, rising awareness of healthcare management among the public, growing healthcare services access, and an increase in government programs to bolster healthcare, will drive the market.

Market Restraints:

  • Side effects associated with using painkillers as a first resort for pain management

Pain medications are frequently the primary line of treatment due to potential side effects such as sickness, drowsiness, constipation, and nausea. Addictive medications can further complicate the situation. Alternative pain management methods, such as pain management devices, can reduce pain without medication. These devices can be used alongside physical therapy or as standalone treatments, reducing side effects and improving pain management.

North America is expected to dominate the market share.

North America has a significant place in the pain management devices market due to its expansive healthcare sector, prominent investment in healthcare, innovative technology, rising chronic pain incidences, environment regulations, and accessibility to healthcare administrations for all regions. The US is also known for its progressed and advanced infrastructure of healthcare and accentuation on advancement in technology.

For instance, in September 2023, Boston Scientific, a US-based medical device manufacturer, announced an agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company that developed and commercialized the Intracept(R) Intraosseous Nerve Ablation System for treating heterogenic pain, a form of chronic low back pain. The transaction includes an upfront cash payment of $850 million and additional contingent payments based on sales performance over the next three years. The Intercept system is the only U.S. Food and Drug Administration-cleared system for heterogenic pain, a minimally invasive, implant-free outpatient procedure that uses targeted radiofrequency energy to improve function and provide long-term relief.

The predominance of persistent pain due to an elderly populace and wrong lifestyle issues may drive the rising demand for pain administration devices in North America. The regulatory initiatives in North America, especially the US, assist the advancement, endorsement, and commercialization of medical devices that manage pain, cultivating innovation and expansion. This accessibility to healthcare services contributes to the higher adoption rate of pain management devices.

Key Developments:

  • April 2024- Medtronic received FDA approval for its Inceptiv(TM) closed-loop spinal cord stimulator, which is designed to treat chronic pain. The device, the first Medtronic SCS to offer a closed-loop feature, automatically adjusts stimulation in real-time based on biological signals along the spinal cord, ensuring therapy is in harmony with daily life motions.
  • December 2023- Nexstim received an order for two NBS 6 systems from a distributor company, which are now more user-friendly and approved for treating major depressive disorder (MDD) in the US and EU, as well as chronic neuropathic pain in the EU.
  • August 2023- Zynex, Inc. introduced three new therapy products for pain management. The first is the Zynex Pro Thoracic Lumbar Sacral Orthosis, a dual-purpose back brace for the spine; the second is the Zynex Pro Wrist, a wrist brace for wrist-related pain management, including carpal tunnel syndrome; and the third is the Zynex Cryoheat, a localized fluid therapy system for home or hospital use.
  • January 2023- CoachCare, a leading RPM and virtual health company acquired Winston-Salem-based NVOLVE for an undisclosed amount, adding NVOLVE's expertise in pain, spine, and orthopedic specialties to its services across South Carolina, North Carolina, Georgia, Texas, Tennessee, and Virginia. FCA Venture Partners is a venture capital firm that invests in early-stage healthcare technology and technology-enabled services companies, while CoachCare, a New York-based remote patient monitoring and virtual health company, offers complete RPM support services.
  • August 2022- Abbott received FDA approval for its Proclaim(TM) Plus spinal cord stimulation system, which offers tailored relief to multiple painful areas and offers more treatment options for evoking pain conditions. The FlexBurst360 therapy, the next generation of Abbott's proprietary BurstDR(TM) stimulation, can be adjusted as a person's therapeutic needs evolve.

Market Segmentation:

Global Pain Management Devices Market is segmented and analyzed as below:

By Devices

  • Electrical Stimulators
  • Neurostimulation Devices
  • Analgesic Infusion Pumps
  • Ablation Devices

By Application

  • Facial & Migraine Pain
  • Neuropathic Pain
  • Cancer Pain
  • Musculoskeletal Pain
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • Italy
  • France
  • Others
  • Middle East and Africa
  • Israel
  • Saudi Arabia
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL PAIN MANAGEMENT DEVICES MARKET BY DEVICES

  • 5.1. Introduction
  • 5.2. Electrical Stimulators
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Neurostimulation Devices
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Analgesic Infusion Pumps
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Ablation Devices
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. GLOBAL PAIN MANAGEMENT DEVICES MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Facial & Migraine Pain
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Neuropathic Pain
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Cancer Pain
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness
  • 6.5. Musculoskeletal Pain
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Others
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness

7. GLOBAL PAIN MANAGEMENT DEVICES MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Devices
    • 7.2.2. By Application
    • 7.2.3. By Country
      • 7.2.3.1. USA
        • 7.2.3.1.1. Market Opportunities and Trends
        • 7.2.3.1.2. Growth Prospects
      • 7.2.3.2. Canada
        • 7.2.3.2.1. Market Opportunities and Trends
        • 7.2.3.2.2. Growth Prospects
      • 7.2.3.3. Mexico
        • 7.2.3.3.1. Market Opportunities and Trends
        • 7.2.3.3.2. Growth Prospects
  • 7.3. South America
    • 7.3.1. By Devices
    • 7.3.2. By Application
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
        • 7.3.3.1.1. Market Opportunities and Trends
        • 7.3.3.1.2. Growth Prospects
      • 7.3.3.2. Argentina
        • 7.3.3.2.1. Market Opportunities and Trends
        • 7.3.3.2.2. Growth Prospects
      • 7.3.3.3. Others
        • 7.3.3.3.1. Market Opportunities and Trends
        • 7.3.3.3.2. Growth Prospects
  • 7.4. Europe
    • 7.4.1. By Devices
    • 7.4.2. By Application
    • 7.4.3. By Country
      • 7.4.3.1. UK
        • 7.4.3.1.1. Market Opportunities and Trends
        • 7.4.3.1.2. Growth Prospects
      • 7.4.3.2. Germany
        • 7.4.3.2.1. Market Opportunities and Trends
        • 7.4.3.2.2. Growth Prospects
      • 7.4.3.3. Italy
        • 7.4.3.3.1. Market Opportunities and Trends
        • 7.4.3.3.2. Growth Prospects
      • 7.4.3.4. France
        • 7.4.3.4.1. Market Opportunities and Trends
        • 7.4.3.4.2. Growth Prospects
      • 7.4.3.5. Others
        • 7.4.3.5.1. Market Opportunities and Trends
        • 7.4.3.5.2. Growth Prospects
  • 7.5. Middle East and Africa
    • 7.5.1. By Devices
    • 7.5.2. By Application
    • 7.5.3. By Country
      • 7.5.3.1. Israel
        • 7.5.3.1.1. Market Opportunities and Trends
        • 7.5.3.1.2. Growth Prospects
      • 7.5.3.2. Saudi Arabia
        • 7.5.3.2.1. Market Opportunities and Trends
        • 7.5.3.2.2. Growth Prospects
      • 7.5.3.3. Others
        • 7.5.3.3.1. Market Opportunities and Trends
        • 7.5.3.3.2. Growth Prospects
  • 7.6. Asia Pacific
    • 7.6.1. By Devices
    • 7.6.2. By Application
    • 7.6.3. By Country
      • 7.6.3.1. China
        • 7.6.3.1.1. Market Opportunities and Trends
        • 7.6.3.1.2. Growth Prospects
      • 7.6.3.2. Japan
        • 7.6.3.2.1. Market Opportunities and Trends
        • 7.6.3.2.2. Growth Prospects
      • 7.6.3.3. India
        • 7.6.3.3.1. Market Opportunities and Trends
        • 7.6.3.3.2. Growth Prospects
      • 7.6.3.4. Australia
        • 7.6.3.4.1. Market Opportunities and Trends
        • 7.6.3.4.2. Growth Prospects
      • 7.6.3.5. South Korea
        • 7.6.3.5.1. Market Opportunities and Trends
        • 7.6.3.5.2. Growth Prospects
      • 7.6.3.6. Taiwan
        • 7.6.3.6.1. Market Opportunities and Trends
        • 7.6.3.6.2. Growth Prospects
      • 7.6.3.7. Thailand
        • 7.6.3.7.1. Market Opportunities and Trends
        • 7.6.3.7.2. Growth Prospects
      • 7.6.3.8. Indonesia
        • 7.6.3.8.1. Market Opportunities and Trends
        • 7.6.3.8.2. Growth Prospects
      • 7.6.3.9. Others
        • 7.6.3.9.1. Market Opportunities and Trends
        • 7.6.3.9.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. NeuroMetrix, Inc.
  • 9.2. Medtronic
  • 9.3. Boston Scientific Corporation
  • 9.4. Zynex Medical
  • 9.5. BioElectronics Corporation
  • 9.6. Pain Management Technologies
  • 9.7. SPR Therapeutics
  • 9.8. Becton, Dickinson, and Company
  • 9.9. Abbott
  • 9.10. Nevro Corp